Ara-290
Peptide therapy: benefits, side effects, cost and protocols
C51H84N16O21
ARA-290 (cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that targets the innate repair receptor without hematopoietic side effects. It has been studied for neuropathy, tissue repair, and chronic inflammatory conditions in multiple human clinical trials.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Moderate Evidence
Who it's for
Who Ara-290 is usually considered for
- Neuropathic pain research
- Tissue repair
- Nerve protection
- Limited human trials or strong preclinical
Mechanism
How Ara-290 works
Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.
Evidence
Key studies
65 papers on PubMed / 32 human trials
- 01
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
- 02
Heij L, Niesters M, Swartjes M et al
Mol Med / Mol Med / Phase 2
ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo.
- 03
ARA 290 safely reduced small fiber neuropathy symptoms and improved pain and physical functioning versus placebo
- 04
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- 05
Brines M, Dunne AN, van Velzen M et al
Mol Med / Mol Med / Phase 2
28 days treatment plus 28 days follow-up
- 06
ARA 290 improved hemoglobin A1c, lipid profiles, neuropathic symptoms, and corneal nerve fiber density in type 2 diabetes
- 07
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
- 08
Dahan A, Dunne A, Swartjes M et al
Mol Med / Mol Med / RCT
- 09
ARA 290 significantly improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients
- 10
Managing fatigue in sarcoidosis - A systematic review of the evidence
Chron Respir Dis / Chron Respir Dis
Compound
Ara-290 compound data
- Formula
- C51H84N16O21
- Mol. weight
- 1257.3 g/mol
- PubChem CID
- 91810664 ↗
- IUPAC
- (4S)-5-[[(1S)-4-amino-1-[[(1S)-1-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-3-amino-1-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxy-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]carbamoyl]-3-oxo-propyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-carboxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-4-oxo-butyl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
FAQ
Ara-290 questions
What is ARA-290?
ARA-290 is a peptide derived from erythropoietin (EPO) researched for tissue repair and neuropathic pain applications without the blood-stimulating effects of EPO.
How does ARA-290 work?
Selectively activates the innate repair receptor (IRR) for tissue-protective effects without erythropoietic activity.
Is ARA-290 legal to buy?
ARA-290 is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy ARA-290?
ARA-290 is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does ARA-290 belong to?
ARA-290 is primarily classified as a tissue repair & healing peptide. Peptides studied for their potential in wound healing, tendon/ligament repair, gut healing, and general tissue regeneration.
What are the research benefits of ARA-290?
ARA-290 has been studied for: Neuropathic pain research, Tissue repair, Nerve protection. Neuropathic pain/repair research peptide.
News
Ara-290 in the news
ARA-290 Peptide: Selective Tissue Signaling and Experimental Research Applications - Seattle Weekly
Seattle Weekly / 1 month ago
The Power of Peptides - Injuries and tissue repair - The Steeple Times
The Steeple Times / 11 months ago
ARA-290: Cytoprotection, Neuroimmune Signaling, and Systems-Level Regulation - Addis Insight
Addis Insight / 7 months ago
A one-two punch for pain control - Science | AAAS
Science | AAAS / 128 months ago
Erythropoietin and its derivatives: from tissue protection to immune regulation | Cell Death & Disease - Nature
Nature / 82 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Ara-290?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.